{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-24-000140","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.703815+00:00","generated_at":"2026-06-04T22:36:56.320969+00:00","sec_items":["1.01","2.02","2.03","3.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KORU Medical reports Q4 rev $7.2M, FY net loss $13.7M; guides 2024 rev $31.2-32.2M","bullets":["Q4 net revenues $7.2M (-2% YoY); gross margin improved to 60.3% (+470bps).","Full year net loss $13.7M ($0.30/sh) includes $6M non-cash tax valuation allowance; Adjusted EBITDA ($6.0M) vs ($6.1M) prior year.","Full year 2024 revenue guidance $31.2-32.2M (10-13% growth); gross margin 59-61%; cash flow breakeven in Q4 2024.","Entered $10M credit facility with HSBC ($5M revolver + $5M term loan; undrawn); warrant for 76,104 shares at $2.12.","EU notified body BSI recommended against continued certification; appeal filed; mgmt expects minimal revenue impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-24-000140","json":"https://secwatch.observer/filing/0001161697-24-000140.json","markdown":"https://secwatch.observer/filing/0001161697-24-000140.md","text":"https://secwatch.observer/filing/0001161697-24-000140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/0001161697-24-000140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:36:56.320969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c9ee1ae2e94ee98bcd9f6857190530223b23e80","claim":"KORU Medical Systems, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $28.5 million, net income ($13.7) million, or ($0.30) per share.","evidence_excerpt":"issued guidance for the full year 2024. Recent Highlights ● Fourth quarter 2023 net revenues of $7.2 million, a 2% decrease from the prior year; Full year 2023 net revenues of $28.5 million, a 2% increase over the prior year ● Full year 6.7% Core business growth (U.S. and International) driven by overall SCIg market growth, share gains and expansion in new","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/0001161697-24-000140-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$28.5 million"},{"label":"Net income","value":"($13.7) million, or ($0.30) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"456a0b1517d1ff255ed6b39eda86e7beb80510ae","claim":"KORU Medical Systems, Inc. entered into Loan and Security Agreement with HSBC Ventures USA Inc. valued at $5,000,000 (effective 2024-03-08).","evidence_excerpt":"On March 8, 2024, KORU Medical Systems, Inc. (the “Company”) entered into a loan and security agreement (the “Loan and Security Agreement”), by and between the Company and HSBC Ventures USA Inc., as lender providing for a revolving credit facility in an aggregate principal amount not to exceed $5,000,000 (the “Revolver”) and a term loan facility in an aggregate principal amount not to exceed $5,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000140/0001161697-24-000140-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"HSBC Ventures USA Inc."},{"label":"Value","value":"$5,000,000"},{"label":"Effective","value":"2024-03-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}